{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:33:24Z","timestamp":1767893604841,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1918854"],"award-info":[{"award-number":["1918854"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1940107"],"award-info":[{"award-number":["1940107"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01MH128085"],"award-info":[{"award-number":["R01MH128085"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG033655"],"award-info":[{"award-number":["U19 AG033655"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>It has become consensus that mild cognitive impairment (MCI), one of the early symptoms onset of Alzheimer\u2019s disease (AD), may appear 10 or more years after the emergence of neuropathological abnormalities. Therefore, understanding the progression of AD biomarkers and uncovering when brain alterations begin in the preclinical stage, while patients are still cognitively normal, are crucial for effective early detection and therapeutic development. In this paper, we develop a Bayesian semiparametric framework that jointly models the longitudinal trajectory of the AD biomarker with a changepoint relative to the occurrence of symptoms onset, which is subject to left truncation and right censoring, in a heterogeneous population. Furthermore, unlike most existing methods assuming that everyone in the considered population will eventually develop the disease, our approach accounts for the possibility that some individuals may never experience MCI or AD, even after a long follow-up time. We evaluate the proposed model through simulation studies and demonstrate its clinical utility by examining an important AD biomarker, ptau181, using a dataset from the Biomarkers of Cognitive Decline Among Normal Individuals (BIOCARD) study.<\/jats:p>","DOI":"10.1093\/biomtc\/ujae048","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T16:15:38Z","timestamp":1716394538000},"source":"Crossref","is-referenced-by-count":1,"title":["A Bayesian semi-parametric model for learning biomarker trajectories and changepoints in the preclinical phase of Alzheimer\u2019s disease"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7850-5928","authenticated-orcid":false,"given":"Kunbo","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Applied Mathematics and Statistics, Johns Hopkins University , Baltimore, MD 21218 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Applied Mathematics and Statistics, Johns Hopkins University , Baltimore, MD 21218 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3882-0181","authenticated-orcid":false,"given":"MeiCheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Johns Hopkins University , Baltimore, MD 21205 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5554-8637","authenticated-orcid":false,"given":"Yanxun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Applied Mathematics and Statistics, Johns Hopkins University , Baltimore, MD 21218 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"2025052120021901400_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1214\/07-AOS574","article-title":"The pseudo-marginal approach for efficient Monte Carlo computations","volume":"37","author":"Andrieu","year":"2009","journal-title":"Annals of Statistics"},{"key":"2025052120021901400_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.0000000000005303","article-title":"Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies","volume":"90","author":"Arenaza-Urquijo","year":"2018","journal-title":"Neurology"},{"key":"2025052120021901400_bib3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"2025052120021901400_bib4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/01621459.2017.1285773","article-title":"Variational inference: a review for statisticians","volume":"112","author":"Blei","year":"2017","journal-title":"Journal of the American Statistical Association"},{"key":"2025052120021901400_bib5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein e type 4 allele and the risk of Alzheimer\u2019s disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"2025052120021901400_bib6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1017\/CBO9780511584589.011","article-title":"Model-based clustering for expression data via a dirichlet process mixture model","volume":"4","author":"Dahl","year":"2006","journal-title":"Bayesian Inference for Gene Expression and Proteomics"},{"key":"2025052120021901400_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1214\/aos\/1176342360","article-title":"A Bayesian analysis of some nonparametric problems","volume":"1","author":"Ferguson","year":"1973","journal-title":"The Annals of Statistics"},{"key":"2025052120021901400_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-06624-y","article-title":"Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer\u2019s disease","volume":"7","author":"Gamberger","year":"2017","journal-title":"Scientific Reports"},{"key":"2025052120021901400_bib9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/alz.12638","article-title":"2022 Alzheimer\u2019s disease facts and figures","volume":"18","author":"Gaugler","year":"2022","journal-title":"Alzheimers & Dementia"},{"key":"2025052120021901400_bib10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s11222-013-9416-2","article-title":"Understanding predictive information criteria for Bayesian models","volume":"24","author":"Gelman","year":"2014","journal-title":"Statistics and Computing"},{"key":"2025052120021901400_bib11","doi-asserted-by":"crossref","first-page":"e1640","DOI":"10.1212\/WNL.0000000000200953","article-title":"CSF Alzheimer disease biomarkers: time-varying relationships with MCI symptom onset and associations with age, sex, and ApoE4","volume":"99","author":"Greenberg","year":"2022","journal-title":"Neurology"},{"key":"2025052120021901400_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1474-4422(19)30440-5","article-title":"Preclinical Alzheimer\u2019s disease: a valid concept","volume":"19","author":"Jack","year":"2020","journal-title":"The Lancet Neurology"},{"key":"2025052120021901400_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"The Lancet Neurology"},{"key":"2025052120021901400_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1212\/WNL.43.1_Part_1.13","article-title":"Education and the prevalence of dementia and Alzheimer\u2019s disease","volume":"43","author":"Katzman","year":"1993","journal-title":"Neurology"},{"key":"2025052120021901400_bib15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/biostatistics\/3.4.547","article-title":"The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure","volume":"3","author":"Law","year":"2002","journal-title":"Biostatistics"},{"key":"2025052120021901400_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1214\/21-AOAS1492","article-title":"Bagel: a Bayesian graphical model for inferring drug effect longitudinally on depression in people with HIV","volume":"16","author":"Li","year":"2022","journal-title":"The Annals of Applied Statistics"},{"key":"2025052120021901400_bib17","doi-asserted-by":"crossref","first-page":"e3104","DOI":"10.1212\/WNL.0000000000010747","article-title":"Sequence of Alzheimer disease biomarker changes in cognitively normal adults: a cross-sectional study","volume":"95","author":"Luo","year":"2020","journal-title":"Neurology"},{"key":"2025052120021901400_bib19","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1002\/sim.9136","article-title":"Penalized regression for left-truncated and right-censored survival data","volume":"40","author":"McGough","year":"2021","journal-title":"Statistics in Medicine"},{"key":"2025052120021901400_bib18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1474-4422(16)00067-3","article-title":"Sex differences in Alzheimer\u2019s disease and other dementias","volume":"15","author":"Mazure","year":"2016","journal-title":"The Lancet Neurology"},{"key":"2025052120021901400_bib20","first-page":"e12374","article-title":"Longitudinal CSF Alzheimer\u2019s disease biomarker changes from middle age to late adulthood","volume":"14","author":"Pettigrew","year":"2022","journal-title":"Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"2025052120021901400_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-019-1299-4","article-title":"Apoe4: an emerging therapeutic target for Alzheimer\u2019s disease","volume":"17","author":"Safieh","year":"2019","journal-title":"BMC Medicine"},{"key":"2025052120021901400_bib22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/WAD.0b013e318211c83c","article-title":"The relationship between education and dementia an updated systematic review","volume":"25","author":"Sharp","year":"2011","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"2025052120021901400_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-021-01709-9","article-title":"Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer\u2019s amyloid, tau and fdg pet status","volume":"11","author":"Shen","year":"2021","journal-title":"Translational Psychiatry"},{"key":"2025052120021901400_bib24","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1214\/17-AOAS1056","article-title":"Biomarker change-point estimation with right censoring in longitudinal studies","volume":"11","author":"Tang","year":"2017","journal-title":"The Annals of Applied Statistics"},{"key":"2025052120021901400_bib25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nature Medicine"},{"key":"2025052120021901400_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fnagi.2019.00074","article-title":"Identifying changepoints in biomarkers during the preclinical phase of Alzheimer\u2019s disease","volume":"11","author":"Younes","year":"2019","journal-title":"Frontiers in Aging Neuroscience"},{"key":"2025052120021901400_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1541-0420.2009.01276.x","article-title":"A Bayesian semiparametric survival model with longitudinal markers","volume":"66","author":"Zhang","year":"2010","journal-title":"Biometrics"}],"container-title":["Biometrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/80\/2\/ujae048\/57825877\/ujae048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/80\/2\/ujae048\/57825877\/ujae048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:02:30Z","timestamp":1747872150000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biometrics\/article\/doi\/10.1093\/biomtc\/ujae048\/7679652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/biomtc\/ujae048","relation":{},"ISSN":["0006-341X","1541-0420"],"issn-type":[{"value":"0006-341X","type":"print"},{"value":"1541-0420","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,3,27]]},"article-number":"ujae048"}}